CA1075604A - Compose antispasmodique - Google Patents

Compose antispasmodique

Info

Publication number: CA1075604A
Authority: CA; Canada
Prior art keywords: composition; allyl; compound; acid; radical
Prior art date: 1976-05-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA278,449A

Other languages

English (en)

Inventor

Rolf Deininger

Erich Wolf

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Chimicasa GmbH

Original Assignee

Chimicasa GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1976-05-18

Filing date

1977-05-16

Publication date

1980-04-15

1977-05-16 Application filed by Chimicasa GmbH filed Critical Chimicasa GmbH

1980-04-15 Application granted granted Critical

1980-04-15 Publication of CA1075604A publication Critical patent/CA1075604A/fr

Status Expired legal-status Critical Current

Links

239000000812 cholinergic antagonist Substances 0.000 title claims abstract description 11
239000000203 mixture Substances 0.000 title claims description 37
230000002048 spasmolytic effect Effects 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 22
230000002921 anti-spasmodic effect Effects 0.000 claims abstract description 12
239000003937 drug carrier Substances 0.000 claims abstract description 5
125000001183 hydrocarbyl group Chemical group 0.000 claims abstract description 4
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
SCCDQYPEOIRVGX-UHFFFAOYSA-N Acetyleugenol Chemical compound COC1=CC(CC=C)=CC=C1OC(C)=O SCCDQYPEOIRVGX-UHFFFAOYSA-N 0.000 claims description 11
239000002775 capsule Substances 0.000 claims description 7
239000002552 dosage form Substances 0.000 claims description 7
ZYEMGPIYFIJGTP-UHFFFAOYSA-N O-methyleugenol Chemical compound COC1=CC=C(CC=C)C=C1OC ZYEMGPIYFIJGTP-UHFFFAOYSA-N 0.000 claims description 6
239000000725 suspension Substances 0.000 claims description 4
150000007933 aliphatic carboxylic acids Chemical class 0.000 claims description 3
125000000217 alkyl group Chemical group 0.000 claims description 3
125000003710 aryl alkyl group Chemical group 0.000 claims description 3
239000008187 granular material Substances 0.000 claims description 3
239000000843 powder Substances 0.000 claims description 3
239000007787 solid Substances 0.000 claims description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 2
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
150000001735 carboxylic acids Chemical class 0.000 claims 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
229940100688 oral solution Drugs 0.000 claims 1
229940100692 oral suspension Drugs 0.000 claims 1
125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
150000001732 carboxylic acid derivatives Chemical class 0.000 abstract description 3
-1 alicyclic carboxylic acids Chemical class 0.000 description 20
208000007101 Muscle Cramp Diseases 0.000 description 12
239000003795 chemical substances by application Substances 0.000 description 8
241000282412 Homo Species 0.000 description 7
239000002253 acid Substances 0.000 description 7
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
208000005392 Spasm Diseases 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
230000008602 contraction Effects 0.000 description 6
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 6
239000000829 suppository Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
238000000034 method Methods 0.000 description 5
PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 4
239000007788 liquid Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
239000003826 tablet Substances 0.000 description 4
229930008281 A03AD01 - Papaverine Natural products 0.000 description 3
229940124575 antispasmodic agent Drugs 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 3
229960004484 carbachol Drugs 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000027939 micturition Effects 0.000 description 3
229960001789 papaverine Drugs 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000011282 treatment Methods 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
241000220479 Acacia Species 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
229910000831 Steel Inorganic materials 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
230000037396 body weight Effects 0.000 description 2
JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
150000004820 halides Chemical class 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
239000008024 pharmaceutical diluent Substances 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
229940049953 phenylacetate Drugs 0.000 description 2
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
230000003578 releasing effect Effects 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
230000003033 spasmogenic effect Effects 0.000 description 2
239000010959 steel Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
229940070710 valerate Drugs 0.000 description 2
UREJOPRZQKQYLG-UHFFFAOYSA-N (2-methoxy-4-prop-1-enylphenyl) benzoate Chemical compound COC1=CC(C=CC)=CC=C1OC(=O)C1=CC=CC=C1 UREJOPRZQKQYLG-UHFFFAOYSA-N 0.000 description 1
IBVLGAQAZKORKI-UHFFFAOYSA-N (2-methoxy-4-prop-1-enylphenyl) pentanoate Chemical compound CCCCC(=O)OC1=CC=C(C=CC)C=C1OC IBVLGAQAZKORKI-UHFFFAOYSA-N 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
UDDCFRISFQHVLR-UHFFFAOYSA-N 1-methoxy-4-(3-methoxyprop-1-enyl)benzene Chemical compound COCC=CC1=CC=C(OC)C=C1 UDDCFRISFQHVLR-UHFFFAOYSA-N 0.000 description 1
YJVWPNSZWZRJBB-UHFFFAOYSA-N 2,3-dimethylcyclohexene-1-carboxylic acid Chemical compound CC1CCCC(C(O)=O)=C1C YJVWPNSZWZRJBB-UHFFFAOYSA-N 0.000 description 1
PSHADDQTSCEAHY-UHFFFAOYSA-N 2-(2-methylpropyl)benzoic acid Chemical compound CC(C)CC1=CC=CC=C1C(O)=O PSHADDQTSCEAHY-UHFFFAOYSA-N 0.000 description 1
CGMMPMYKMDITEA-UHFFFAOYSA-N 2-ethylbenzoic acid Chemical compound CCC1=CC=CC=C1C(O)=O CGMMPMYKMDITEA-UHFFFAOYSA-N 0.000 description 1
QXKNDUSXGFIHHU-UHFFFAOYSA-N 2-methylcyclopentene-1-carboxylic acid Chemical compound CC1=C(C(O)=O)CCC1 QXKNDUSXGFIHHU-UHFFFAOYSA-N 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
MOPPBIFWYGBGIN-UHFFFAOYSA-N 4,4-dipropylcyclohexane-1-carboxylic acid Chemical compound CCCC1(CCC)CCC(C(O)=O)CC1 MOPPBIFWYGBGIN-UHFFFAOYSA-N 0.000 description 1
UVZMNGNFERVGRC-UHFFFAOYSA-N 4-cyclohexylbutanoic acid Chemical compound OC(=O)CCCC1CCCCC1 UVZMNGNFERVGRC-UHFFFAOYSA-N 0.000 description 1
BYHDDXPKOZIZRV-UHFFFAOYSA-N 5-phenylpentanoic acid Chemical compound OC(=O)CCCCC1=CC=CC=C1 BYHDDXPKOZIZRV-UHFFFAOYSA-N 0.000 description 1
208000004998 Abdominal Pain Diseases 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
229930003347 Atropine Natural products 0.000 description 1
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
241000725101 Clea Species 0.000 description 1
208000002881 Colic Diseases 0.000 description 1
206010010305 Confusional state Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
ZOGNBLKDKPCKGB-UHFFFAOYSA-N Eugenyl benzoate Chemical compound COC1=CC(CC=C)=CC=C1OC(=O)C1=CC=CC=C1 ZOGNBLKDKPCKGB-UHFFFAOYSA-N 0.000 description 1
206010017999 Gastrointestinal pain Diseases 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
206010029148 Nephrolithiasis Diseases 0.000 description 1
241001442654 Percnon planissimum Species 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
208000032140 Sleepiness Diseases 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
208000006568 Urinary Bladder Calculi Diseases 0.000 description 1
238000006959 Williamson synthesis reaction Methods 0.000 description 1
206010000210 abortion Diseases 0.000 description 1
231100000176 abortion Toxicity 0.000 description 1
IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
239000011149 active material Substances 0.000 description 1
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
239000003708 ampul Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
229960000396 atropine Drugs 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
201000001883 cholelithiasis Diseases 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
229910052681 coesite Inorganic materials 0.000 description 1
238000013329 compounding Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
229910052906 cristobalite Inorganic materials 0.000 description 1
229940109275 cyclamate Drugs 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
238000013016 damping Methods 0.000 description 1
125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
125000005066 dodecenyl group Chemical group C(=CCCCCCCCCCC)* 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
238000006266 etherification reaction Methods 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
FPIQZBQZKBKLEI-UHFFFAOYSA-N ethyl 1-[[2-chloroethyl(nitroso)carbamoyl]amino]cyclohexane-1-carboxylate Chemical compound ClCCN(N=O)C(=O)NC1(C(=O)OCC)CCCCC1 FPIQZBQZKBKLEI-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
208000001130 gallstones Diseases 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000006038 hexenyl group Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
IUSBVFZKQJGVEP-SNAWJCMRSA-N isoeugenol acetate Chemical compound COC1=CC(\C=C\C)=CC=C1OC(C)=O IUSBVFZKQJGVEP-SNAWJCMRSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000000155 melt Substances 0.000 description 1
230000005906 menstruation Effects 0.000 description 1
KSSDATBGROGULK-UHFFFAOYSA-N methyl 2-phenylethaneperoxoate Chemical compound COOC(=O)CC1=CC=CC=C1 KSSDATBGROGULK-UHFFFAOYSA-N 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000003387 muscular Effects 0.000 description 1
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
125000001196 nonadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical compound CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 description 1
125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
125000005064 octadecenyl group Chemical group C(=CCCCCCCCCCCCCCCCC)* 0.000 description 1
125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000005592 polycycloalkyl group Polymers 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
230000037321 sleepiness Effects 0.000 description 1
239000002002 slurry Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229910052682 stishovite Inorganic materials 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
125000005063 tetradecenyl group Chemical group C(=CCCCCCCCCCCCC)* 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
125000005040 tridecenyl group Chemical group C(=CCCCCCCCCCCC)* 0.000 description 1
125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229910052905 tridymite Inorganic materials 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
125000005065 undecenyl group Chemical group C(=CCCCCCCCCC)* 0.000 description 1
125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
ABDKAPXRBAPSQN-UHFFFAOYSA-N veratrole Chemical compound COC1=CC=CC=C1OC ABDKAPXRBAPSQN-UHFFFAOYSA-N 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
238000010792 warming Methods 0.000 description 1
125000005023 xylyl group Chemical group 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/007—Esters of unsaturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
- C07C69/01—Vinyl esters
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/12—Acetic acid esters
- C07C69/16—Acetic acid esters of dihydroxylic compounds

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Emergency Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CA278,449A 1976-05-18 1977-05-16 Compose antispasmodique Expired CA1075604A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
LU74973A LU74973A1 (fr)	1976-05-18	1976-05-18

Publications (1)

Publication Number	Publication Date
CA1075604A true CA1075604A (fr)	1980-04-15

Family

ID=19728242

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA278,449A Expired CA1075604A (fr)	1976-05-18	1977-05-16	Compose antispasmodique

Country Status (9)

Country	Link
JP (1)	JPS52142030A (fr)
BE (1)	BE854716A (fr)
CA (1)	CA1075604A (fr)
DE (1)	DE2719623A1 (fr)
ES (1)	ES458893A1 (fr)
FR (1)	FR2362625A1 (fr)
GB (1)	GB1572119A (fr)
LU (1)	LU74973A1 (fr)
NL (1)	NL7705436A (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2466458A1 (fr) *	1979-09-27	1981-04-10	Mathieu Andre	Nouveaux medicaments derives de l'eugenol
US4533746A (en) *	1983-06-16	1985-08-06	International Flavors & Fragrances Inc.	2-Methoxy-4-(2-methylpropenyl) phenyl ester of isobutyric acid, flavor use thereof and process for preparing same

1976
- 1976-05-18 LU LU74973A patent/LU74973A1/xx unknown
1977
- 1977-05-03 DE DE19772719623 patent/DE2719623A1/de not_active Ceased
- 1977-05-16 CA CA278,449A patent/CA1075604A/fr not_active Expired
- 1977-05-16 FR FR7714850A patent/FR2362625A1/fr active Granted
- 1977-05-16 GB GB2043377A patent/GB1572119A/en not_active Expired
- 1977-05-16 BE BE177645A patent/BE854716A/fr not_active IP Right Cessation
- 1977-05-17 NL NL7705436A patent/NL7705436A/xx not_active Application Discontinuation
- 1977-05-17 JP JP5605377A patent/JPS52142030A/ja active Pending
- 1977-05-18 ES ES458893A patent/ES458893A1/es not_active Expired

Also Published As

Publication number	Publication date
FR2362625B1 (fr)	1980-01-18
GB1572119A (en)	1980-07-23
NL7705436A (nl)	1977-11-22
LU74973A1 (fr)	1977-12-22
DE2719623A1 (de)	1977-12-08
JPS52142030A (en)	1977-11-26
FR2362625A1 (fr)	1978-03-24
BE854716A (fr)	1977-09-16
ES458893A1 (es)	1978-03-16

Legal Events

Date	Code	Title	Description
1997-04-15	MKEX	Expiry

Publication	Publication Date	Title
CA1239587A (fr)	1988-07-26	Compose d'acides gras pour abaisser les taux de cholesterol et de triglycerides sanguins
KR850000072B1 (ko)	1985-02-18	5-(2-포르밀-3-히드록시페녹시)펜타노익산류
EP0455783B1 (fr)	1996-03-13	Utilisation d'acide nervonique et d'acides gras a longues chaines dans le traitement des troubles provoques par la demyelinisation
JPH07508000A (ja)	1995-09-07	１，２，３−トリアゾール及びイミダゾール化合物並びにそれらの抗腫瘍用途
IE58015B1 (en)	1993-06-16	Tigogenin-cellobioside for treating hypercholesterolemia and arteriosclerosis
TNSN91049A1 (fr)	1992-10-25	Benzimidazoles substitues, procedes en vue de leur preparation, et leur emploi pharmaceutique
DE3686168T2 (de)	1993-01-14	Hydroxyphenylthioalkylketoalkohole.
US4208421A (en)	1980-06-17	Therapeutic compositions for the treatment of connective tissues diseases
IE44639B1 (en)	1982-02-10	Oxadiazoloyl-substituted compounds having pharmacological activity
BE898524A (fr)	1984-06-22	Analogues d'amino-prostaglandines à substituant 7-oxabicycloheptane, ayant des propriétés thérapeutiques.
EP0623138A1 (fr)	1994-11-09	Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
US4119730A (en)	1978-10-10	Treating muscle spasms
US4540709A (en)	1985-09-10	Method for treatment of diseases mediated by PAF using 5-allyl-2-(3,4-Dimethoxyphenyl)-3a,α-methoxy-3-methyl-2,3,3a,6-tetrahydro-6-oxobenzofuran
Cordier et al.	1982	The Influence of Chromium, Manganese and Copper on the Tensile Properties and Stress Corrosion Cracking of the Weldable AlZn 5 Mg 1. 7 Alloy
US4758591A (en)	1988-07-19	Dialkanoyloxybenzylidene dialkanoate
US4520029A (en)	1985-05-28	Farnesene derivatives, mucosal stabilizing compositions and method of manufacturing the same
US4510159A (en)	1985-04-09	(+)-Cyanidan-3-ol derivatives, pharmaceutical preparations that contain such compounds, and the use of the latter to treat liver or venous diseases
US6071898A (en)	2000-06-06	Asiatic acid derivatives having modified A-ring
US4423073A (en)	1983-12-27	Fluorinated diaminopentene derivatives
US3646067A (en)	1972-02-29	Adamantylaminophenoxypropanols and ester derivatives
GB1572119A (en)	1980-07-23	Pharmaceutical spasmolytic composition
Gualtieri et al.	1974	Cyclopentane analog of muscarone
JP2557090B2 (ja)	1996-11-27	カフェー酸誘導体およびそれを含む医薬組成物
CA1080254A (fr)	1980-06-24	Amides de la norfenfluramine
CH627732A5 (de)	1982-01-29	Verfahren zur herstellung von substituierten phenoxypropanolamin.